Molly Harper
Director/Board Member chez CATALYST PHARMACEUTICALS, INC.
Fortune : 85 008 $ au 31/03/2024
Profil
Molly Harper is currently working as an Independent Director at Catalyst Pharmaceuticals, Inc., Director at PreciseDx Ltd., and Chief Business Officer at Synlogic, Inc. She previously worked as Head-Endocrinology Division at Genzyme Corp., Executive Vice President-Operations at Relmada Therapeutics, Inc., and Senior Vice President at Akcea Therapeutics, Inc. She completed her undergraduate degree at Cornell University and earned an MBA from The Wharton School of the University of Pennsylvania.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 28/03/2024 | 5 333 ( 0,00% ) | 85 008 $ | 31/03/2024 |
Postes actifs de Molly Harper
| Sociétés | Poste | Début |
|---|---|---|
| CATALYST PHARMACEUTICALS, INC. | Director/Board Member | 29/06/2021 |
| SYNLOGIC, INC. | Corporate Officer/Principal | 27/09/2021 |
PreciseDx Ltd.
 PreciseDx Ltd. Data Processing ServicesTechnology Services PreciseDx Ltd. is a British AI company that specializes in oncology diagnostics. The company is based in Altrincham, UK. The company leverage the analysis of morphology features from histology slides to provide more precise patient-specific risk information. The company's proprietary morphology feature array™ allows clinical teams to have access to unmatched insights and accurate, actionable intelligence for disease state characterization to determine the best treatment for each patient. PreciseDx creates disease-specific assays that deliver new levels of pathology information and insight on each patient's risk profile and likely outcomes to aid in treatment decision-making. The company was founded in 2019. Wayne L. Brinster has been the CEO of the company since 2021. | Director/Board Member | 15/03/2022 |
Anciens postes connus de Molly Harper
| Sociétés | Poste | Fin |
|---|---|---|
| AKCEA THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
| RELMADA THERAPEUTICS, INC. | Chief Operating Officer | - |
Formation de Molly Harper
| Cornell University | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| CATALYST PHARMACEUTICALS, INC. | Health Technology |
| RELMADA THERAPEUTICS, INC. | Health Technology |
| SYNLOGIC, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Akcea Therapeutics, Inc.
 Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA. | Health Technology |
PreciseDx Ltd.
PreciseDx Ltd. Data Processing ServicesTechnology Services PreciseDx Ltd. is a British AI company that specializes in oncology diagnostics. The company is based in Altrincham, UK. The company leverage the analysis of morphology features from histology slides to provide more precise patient-specific risk information. The company's proprietary morphology feature array™ allows clinical teams to have access to unmatched insights and accurate, actionable intelligence for disease state characterization to determine the best treatment for each patient. PreciseDx creates disease-specific assays that deliver new levels of pathology information and insight on each patient's risk profile and likely outcomes to aid in treatment decision-making. The company was founded in 2019. Wayne L. Brinster has been the CEO of the company since 2021. | Technology Services |
